Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GOT1 | P17174 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazine SCHEMBL2655942 | 0.96 | GAA (0.37) | GAAMAPTALDH1A1PTGS1PTGS2 | |
| SCHEMBL7673909 | 0.93 | ALDH1A1 (0.43) | GAAMAPTALDH1A1PTGS1PTGS2 | |
| SCHEMBL10265141 | 0.81 | ALDH1A1 (0.39) | GAAMAPTALDH1A1KDM4EHTT | |
| Hydrochloric Acid SCHEMBL1205235 | 0.79 | ALDH1A1 (0.38) | GAAMAPTALDH1A1KDM4EHTT | |
| SCHEMBL10839658 | 0.78 | MEN1 (0.39) | GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL1189327 | 0.74 | MAPT (0.43) | GAAMAPTALDH1A1KDM4EHTT | |
| SCHEMBL31314253 | 0.74 | TDP1 (0.37) | MAPTALDH1A1PTGS1PTGS2KDM4E | |
| SCHEMBL5120892 | 0.74 | TDP1 (0.37) | MAPTALDH1A1PTGS1PTGS2KDM4E | |
| SCHEMBL7832619 | 0.73 | HTT (0.33) | HTT | |
| SCHEMBL10840941 | 0.73 | ALDH1A1 (0.41) | GAAMAPTALDH1A1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017190707-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 如东赛默罗生物科技有限公司 | 2017-11-09 | — | — | WO | disclosed |
| EP-1149102-B1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2004-12-08 | — | — | EP | disclosed |
| US-6630471-B1 | Central nervous system disorders | MERCK SHARP & DOHME LTD. (GB) | 2003-10-07 | — | — | US | disclosed |
| US-20030158203-A1 | Triazolo-pyridazine derivatives as ligands for GABA receptors | MERCK & CO., INC. | 2003-08-21 | — | — | US | disclosed |
| EP-1107967-B1 | TRIAZOLOPYRIDAZINE DERIVATIVES FOR ENHANCING COGNITION | MERCK SHARP & DOHME (GB) | 2003-05-14 | — | — | EP | disclosed |
| EP-1090004-B1 | A SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVE, PHARMACEUTICAL COMPOSITIONS MADE THEREFROM | MERCK SHARP & DOHME (GB) | 2003-05-07 | — | — | EP | disclosed |
| US-6500828-B1 | TREATMENT OF ANXIETY AND CONVULSIONS | MERCK SHARP & DOHME LTD. (GB) | 2002-12-31 | — | — | US | disclosed |
| US-6444666-B1 | SUCH AS ALZHEIMER'S DISEASE; SUBSTITUTED 1,2,4-TRIAZOLO(4,3-B) PYRIDAZINE DERIVATIVES ARE LIGANDS FOR GABA RECEPTORS; CONVULSANT ACTIVITY IS REDUCED OR ELIMINATED | MERCK SHARP & DOHME LTD. (GB) | 2002-09-03 | — | — | US | disclosed |
| EP-1149102-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 2001-10-31 | — | — | EP | disclosed |
| US-6297235-B1 | ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LTD. (GB) | 2001-10-02 | — | — | US | disclosed |
| WO-2000044752-A1 | TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158203-A1 | Triazolo-pyridazine derivatives as ligands for GABA receptors | GABBR1, GABRA3, GABRA5 | GAA 4421/4885MAPT 1219/4885ALDH1A1 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.